Anhui Zhifei Longcom: ZF2001

Anhui Zhifei Longcom: ZF2001

Vaccine Type: Protein Subunit

This vaccine may also be referred to as RBD-Dimer, Zifivax

About Trial Phases

Phase 1: 4 Trials

NCT04445194
China
NCT04636333
China
NCT04550351, ChiCTR2000035691
China
NCT04961359
China

Phase 2: 2 Trials

NCT04466085
China
NCT04813562
China

Phase 3: 2 Trials

ChiCTR2100050849
China
ChiCTR2000040153, NCT04646590
China, Ecuador, Indonesia, Pakistan, Uzbekistan

Approvals

3 Countries

Registered Trials

ChiCTR2100050849
Phase 3
China
Total Enrollment: 14,600
Official Trial Registration:
- ChiCTR2100050849(Opens in new tab/window)
ChiCTR2000040153, NCT04646590
Phase 3
China, Ecuador, Indonesia, Pakistan, Uzbekistan
Total Enrollment: 29,000
Official Trial Registration:
- ChiCTR2000040153(Opens in new tab/window)
- NCT04646590(Opens in new tab/window)
NCT04466085
Phase 2
China
Total Enrollment: 900
Official Trial Registration:
- NCT04466085(Opens in new tab/window)
NCT04813562
Phase 2
China
Total Enrollment: 480
Official Trial Registration:
- NCT04813562(Opens in new tab/window)
NCT04445194
Phase 1
China
Total Enrollment: 50
Official Trial Registration:
- NCT04445194(Opens in new tab/window)
NCT04636333
Phase 1
China
Total Enrollment: 216
Official Trial Registration:
- NCT04636333(Opens in new tab/window)
NCT04550351, ChiCTR2000035691
Phase 1
China
Total Enrollment: 50
Official Trial Registration:
- NCT04550351(Opens in new tab/window)
- ChiCTR2000035691(Opens in new tab/window)
NCT04961359
Phase 1
China
Total Enrollment: 75
Official Trial Registration:
- NCT04961359(Opens in new tab/window)

© 2021 McGill COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form